BV100 Philippines trial plans list two hospitals. Witfire checks RIV-TARGET, revised readout dates, the antibiotic regimen and pending local recruitment.
Nerandomilast Philippines trial plans name three hospitals. Inside the Phase 3 systemic sclerosis study, its evidence, endpoints and pending local recruitment.
Philippine FDA CPR renewal guidance confirms when an expired medical-device CPR remains valid during review and which records ...
Alevia-B is receiving fresh coverage in the Philippines through PascualLab’s 80th-anniversary portfolio campaign. Each tablet combines paracetamol with vitamins B1, B6 and B12. The Philippine FDA ...
The ravulizumab ARTEMIS trial has been terminated at 555 patients. Read alone it is one failed study. Read against the registry it is the sixth attempt to take a rare-disease drug into a large ...
RENGEVITY-201 trial begins Phase 2 testing of pegrizeprument against tacrolimus in kidney transplantation. We examine its ...
A bright clinical concept image showing the stabilizer ceiling in amyloidosis, where modern background therapy reduces the detectable benefit of add-on drugs. HELIOS-B cleared its endpoint.
Bright scientific image illustrating eplontersen TTR silencing in transthyretin amyloid cardiomyopathy, cardiac amyloid burden and the challenge of adding a silencer to stabilizer therapy. HELIOS-B ...
RP1 showed a roughly one-in-three response rate, durable activity, and a favorable safety profile in anti-PD-1-failed advanced melanoma. The FDA rejected it anyway — not because the drug had obviously ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results